All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
132 results for "Cancer"
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients with MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Protocol No
NU-14H09
Sub Category
Hematologic/Blood Related Cancers
A Phase Ib Study of Cobimetinib Administered In Combination With Niraparib, With Or Without Atezolizumab, to Patients With Advanced Platinum-Sensitive Ovarian Cancer
The purpose of this study is to evaluate the safety and efficacy of study drug cobimentinib given in combination with niraparib with or without atezolizumab in patients with platinum sensitive ovarian cancer
Protocol No
HOFFMANN-LAROCHE-YO40482
Sub Category
Gynecologic Cancers
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Venetoclax and Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL
Protocol No
ECOG-EA9152
Sub Category
Hematologic/Blood Related Cancers
A Phase 1 Study with an Expansion Cohort of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
We want to find out what effects, good and/or bad, the drug combination of brentuximab vedotin and ipilimumab used together at different dose levels have on you and your relapsed or refractory Hodgkin lymphoma.
Protocol No
ECOG-E4412
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
Phase II Study of Maintenance Ruxolitinib after Allogeneic Stem Cell Transplantation for Older Patient with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)
Ruxolitinib after Allogeneic Stem Cell Transplantation in AML
Protocol No
DF-HCC-17-273AML-ASCT
Sub Category
Hematologic/Blood Related Cancers
Monoclonal Antibody-Based Sequential Therapy For Deep Remission In Multiple Myeloma MASTER TRIAL
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER)
Protocol No
UAB-1735-MASTER
Sub Category
Hematologic/Blood Related Cancers
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
Comparing Radiation Plus Antibody Therapy to Radiation Plus Immune Therapy in People With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Protocol No
NRG-HN004
Sub Category
Head and Neck Cancers
A Phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent Cervical Carcinoma
Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma
Protocol No
IOVANCE-C-145-04-CERVICAL
Sub Category
Gynecologic Cancers
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
The purpose of the study is to compare any good and bad effects of using a combination of the investigational agents cediranib and olaparib, to using the standard chemotherapy, or cediranib alone, or olaparib alone.
Protocol No
NRG-GY005
Sub Category
Gynecologic Cancers
Study Evaluating Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-Wall
Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall
Protocol No
IIT-BEDI-HYPOFRACTIONATED
Sub Category
Sarcoma
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation to the usual whole-brain radiation. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It also is possible that avoiding the hippocampus could have no benefit or could cause other side effects. Hippocampal avoidance also could lessen the effectiveness of whole-brain radiation. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the addition of the hippocampal avoidance technique to whole-brain radiation therapy should decrease the chance of side effects on memory or thinking by at least 14.5%.
Protocol No
NRG-CC003
Sub Category
Brain and Spine Cancers
Thoracic Cancers
Impact of Expiratory Muscle Strength Training (EMST) on Swallowing Function in Persons Undergoing Radiotherapy +/- Chemotherapy for Cancers of the Head and Neck
Impact of EMST on Swallowing Function in Head/Neck Ca Pts Undergoing Radiotherapy +/- Chemotherapy
Protocol No
IIT-PAULOSKI-UWM-EMST
Sub Category
Head and Neck Cancers
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Radiation and Cisplatin with or without Triapine in Newly Diagnosed Cervical Cancer
Protocol No
NRG-GY006
Sub Category
Gynecologic Cancers
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects with Multiple Myeloma
A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma
Protocol No
AMGEN-20170122-AMG701
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies
Protocol No
ABBVIE-M15-913
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers